Zura Bio Ltd (ZURA) Form 8-K — Oct 27, 2026
Zura Bio reported Q3 2026 results with a net loss of $25.8 million ($0.20 per share) versus $18.0 million a year ago, as R&D spend rose to $19.5 million from $11.9 million on Phase 2 execution. The company confirmed its lead Phase 2 readouts remain on track: TibuSHIELD in hidradenitis suppurativa (247 participants enrolled, exceeding target) reports topline in Q4 2026, and TibuSURE in systemic sclerosis (91 participants) reports in H1 2027, with a third Phase 2 (NEXUS-PMR) set to start by year-end 2026. Zura ended the quarter with $187.7 million in cash, which management expects to fund operations through at least the end of 2028 — covering all three data readouts.
Key figures
- Revenue
- 0
- Total Assets
- 194629000
- Cash Position
- 187652000
- Shares Outstanding
- 96306411
- Cash Runway
- through at least end of 2028
- Ga Expenses Q3
- 9282000
- Rd Expenses Q3
- 19491000
- Tibu SURE enrollment
- 91
- Rd Expenses Q3 Prior Year
- 11948000
- Tibu SHIELD enrollment
- 247
- Total Shares Including Warrants M
- 125.6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.